NCT05323630View on ClinicalTrials.gov

Evaluation of the Use of the Renuvion APR System in the Labia

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

April 23, 2024

Study Completion Date

April 23, 2024

Conditions
Labia EnlargedLabium; Hypertrophy
Interventions
DEVICE

Renuvion APR System

The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.

Trial Locations (1)

20037

Allison Plastic Martinez, Washington D.C.

Sponsors

Lead Sponsor

Apyx Medical
All Listed Sponsors
lead

Apyx Medical

INDUSTRY

NCT05323630 - Evaluation of the Use of the Renuvion APR System in the Labia | Biotech Hunter | Biotech Hunter